N/A N=53 MIRODERM H2H DFU Study
Diabetic Foot Ulcer
Primary: Percentage of Participants — 57.89 Percentage of participants with healed u
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=104 Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
Pancreatectomy for Chronic Pancreatitis
Primary: Percentage of Patients Who Were Insulin Independent After Islet Autotransplantation (IAT) at Day 365±14 Days After Transplant. — 20.0; 21.2 Percentage of participants…
Phase 3 N=838 An Efficacy and Safety Study of Fremanezumab in Adults With Migraine
Migraine Prophylaxis
Primary: DB Period: Change From Baseline in Monthly Average Number of Migraine Days During the 12-Week Period After the First Dose of Fremanezumab — -0.6; -3.7; -4.1 days/month…
Phase 2 N=4 High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation
Neuroblastoma
Primary: Assess the Impact of High-dose 3F8/GM-CSF on Relapse-free Survival
N/A N=11 Inducibility and Stability of Ventricular Tachycardia Inpatients Undergoing VT Ablation Under General Anesthesia
Ventricular Tachycardia
Primary: Number of Participants Who Had Inducible Ventricular Tachycardia Under General Anesthesia. — 7; 5; 5 participants
Phase 4 N=710 FSH in GnRH-AntagoniST Controlled Ovarian Hyperstimulation Cycles (FAST)
Infertility
Primary: Clinical Pregnancy Rate — 36.93; 39.66 percentage of participants — p=0.49
N/A N=47 Randomized Trial Comparison of Ototoxicity Monitoring Programs
Cisplatin Ototoxicity · Hearing Loss
Primary: Number of Participants With an Ototoxic Hearing Shift — 15; 8 Participants — p=.27
Early Phase 1 N=14 Valproic Acid in Subjects With Intact Cognition - Proof of Concept Study
Alzheimer's Disease
Primary: Frequency of Adverse Events Over the Duration of the Study by Study Arm — 8; 1 Participants
N/A N=17,987 Abbott Laboratories Alinity s Blood Screening Assays - Clinical Evaluation Protocol
Healthy
Primary: Alinity s HBsAg Assay Specificity — 16985; 6; 2 Participants
N/A N=61 Chemotherapy Induced Peripheral Neuropathy. Could Physical Therapy Help Treat Symptoms?
Breast Cancer · Peripheral Neuropathy, Secondary to Drugs or Chemicals
Primary: Percentage of Participants With 'Pain' or 'no Pain' as Measured by the Numeric Pain Rating Scale — 30; 49; 70; 51 percentage of participants — p=0.053
Phase 1 N=33 Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma
Melanoma
Primary: Number of Patients With Severe Toxicities During the Study Treatment Period — 0 Participants
Phase 2 N=110 Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer
Head and Neck Cancer
Primary: Progression Free Survival (PFS) — 87.7; 92.5 Probability (%) — p=0.1225
N/A N=22 Optical Head-Mounted Display Technology for Low Vision Rehabilitation
Retinal Dystrophies · Healthy
Primary: Change in the Planimetric Area of Goldmann Visual Field With the Use of Head-mounted Display Technology Compared to Baseline (Measured in Degrees Squared) — 563.08…
N/A N=400 The Health Access and Recovery Peer Program
Hypertension · Arthritis · Coronary Artery Disease
Primary: Health Related Quality of Life (HRQOL) — 32.73; 32.74; 34.49; 33.89 score on a scale
Phase 3 N=84 Prasugrel for Prevention of Early Saphenous Vein Graft Thrombosis
Coronary Artery Bypass
Primary: Prevalence of Intragraft Thrombus at 12-month Follow-up Optical Coherence Tomography Imaging — 14; 14 Participants — p=0.78